Viridian Therapeutics (VRDN) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...
Business Insider1mon
Positive Outlook for Viridian Therapeutics: Analyst Reaffirms Buy Rating on Strong Competitive Position and Efficacy of VRDN-001
In a report released today, Serge Belanger from Needham maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report), with a price target of $38.00. Discover outperforming stocks ...
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $35.70 Average Price Target from Analysts
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the company, Ratings ...